T-Rex 2X Long MSTR Daily Target ETF vs 10X Genomics Inc — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $39.84 (market cap $809.00M), while 10X Genomics Inc trades at $81.18 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 12.4× T-Rex 2X Long MSTR Daily Target ETF's market cap, and 10X Genomics Inc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Long MSTR Daily Target ETF for 18 Days and 10X Genomics Inc for 91 Days on average.
| MSTU | TXG | |
|---|---|---|
Market Cap | $809.00M | $10.07B |
Volume | 4,577,465 | 5,657,286 |
Sector | Leveraged / Inverse | Health |
52-Week High | $451.00 | $97.74 |
52-Week Low | $14.60 | $11.48 |
Typical Hold Time | 18 Days | 91 Days |
Enterprise Value | — | $9.59B |
Signals from Pluang's Aura AI — not financial advice
MSTU trades at $40.50, up 2.66% with a bearish technical signal from moving averages while oscillators remain neutral. The stock faces significant resistance at $41-$43 levels with support at $37-$35. Recent corporate actions include a 10:1 reverse stock split effective August 24, 2026, and a $0.29 dividend declaration for H2-2026.
The leveraged ETF structure presents both opportunity and risk - offering amplified exposure to MSTR but with daily rebalancing that can erode value during volatility. Key risks include the compounding effect of daily leverage and Bitcoin price sensitivity. Investors should monitor the underlying stock's fundamentals and Bitcoin market dynamics closely.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →